Troxacitabine

Drug Profile

Troxacitabine

Alternative Names: BCH 4556; SGX-145; SPD 758; Troxatyl

Latest Information Update: 24 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer SGX Pharmaceuticals; Shire
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Pancreatic cancer; Renal cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 20 Aug 2008 SGX Pharmaceuticals has been acquired by Eli Lilly
  • 30 Aug 2006 Discontinued - Phase-II/III for Acute myeloid leukaemia in European Union (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top